Nguyen Nam P, North Debra, Smith Herbert J, Dutta Suresh, Alfieri Alan, Karlsson Ulf, Lee Howard, Martinez Tomas, Lemanski Claire, Nguyen Ly M, Ludin Adir, Sallah Sabah
Department of Radiation Oncology, University of Arizona, 101 N Campbell Avenue, P.O Box 45081 Tucson, AZ 85724-508, USA.
Surg Oncol. 2006 Dec;15(4):199-203. doi: 10.1016/j.suronc.2006.12.002. Epub 2007 Feb 5.
We would like to assess the safety and effectiveness of prophylactic percutaneous endoscopic gastrostomy (PEG) tube feedings during concurrent chemoradiation for head and neck cancer.
Patients who underwent chemotherapy and radiation for head and neck malignancies were evaluated for their ability to resume oral feeding following treatment. All patients underwent PEG tube placement prior to the treatment because of the expected mucositis. Gastrostomy tubes were removed following treatment when the patients were able to resume oral feedings without aspiration.
Between March 1999 and 2006, 104 patients with locally advanced head and neck cancer underwent concurrent chemotherapy and radiation. One patient declined placement of gastrostomy tube. Ninety patients (86%) developed grade 3-4 mucositis during chemoradiation. Five patients died during treatment from aspiration pneumonia and sepsis. One hundred two patients lost weight during treatment. The mean and median weight loss during concurrent therapy was, respectively, 8.5 and 8 kg (1-23.5 kg). Following treatment, tube feedings were continued 1-41 months (mean: 8 months; median: 5 months) because of continued weight loss, chronic dysphagia, or aspiration. At a median follow-up of 19 months (1-62 months), no patient developed serious complications from tube feedings.
Dysphagia resulting from the severe mucositis produced severe weight loss, despite tube feedings. Gastrostomy tube feedings are safe. Gastrostomy tubes should be placed prophylactically for patients undergoing chemoradiation for head and neck cancer.
我们旨在评估预防性经皮内镜下胃造口术(PEG)管饲在头颈部癌同步放化疗期间的安全性和有效性。
对头颈部恶性肿瘤患者进行化疗和放疗后,评估其治疗后恢复经口进食的能力。由于预期会发生黏膜炎,所有患者在治疗前均接受了PEG管置入。当患者能够恢复经口进食且无误吸时,在治疗后拔除胃造口管。
1999年3月至2006年期间,104例局部晚期头颈部癌患者接受了同步化疗和放疗。1例患者拒绝置入胃造口管。90例患者(86%)在放化疗期间发生3 - 4级黏膜炎。5例患者在治疗期间死于吸入性肺炎和败血症。102例患者在治疗期间体重减轻。同步治疗期间体重减轻的均值和中位数分别为8.5 kg和8 kg(1 - 23.5 kg)。治疗后,由于持续体重减轻、慢性吞咽困难或误吸,管饲持续了1 - 41个月(均值:8个月;中位数:5个月)。在中位随访19个月(1 - 62个月)时,没有患者因管饲出现严重并发症。
尽管进行了管饲,但严重黏膜炎导致的吞咽困难仍造成了严重体重减轻。胃造口管饲是安全的。对于接受头颈部癌放化疗的患者,应预防性置入胃造口管。